image
Jasper Therapeutics, Inc. JSPRW
Healthcare - Biotechnology - NASDAQ - US
Watchlist
$ 0.186
0 %
$ 332 M
Market Cap
-0.05
P/E
1. INTRINSIC VALUE

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and novel conditioning regimens for stem cell transplantation and ex-vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.[ Read More ]

The intrinsic value of one JSPRW stock under the base case scenario is HIDDEN Compared to the current market price of 0.186 USD, Jasper Therapeutics, Inc. is HIDDEN

JSPRW Intrinsic Value
HIDDEN
SHOW
2. FUNDAMENTAL ANALYSIS

Price Chart JSPRW

image
FINANCIALS
0 REVENUE
0.00%
Growth Rates
1Year 0.00%
3Years 0.00%
5Years 0.00%
7Years 0.00%
10Years 0.00%
-68.9 M OPERATING INCOME
-34.50%
Growth Rates
1Year -34.50%
3Years -49.32%
5Years 0.00%
7Years 0.00%
10Years 0.00%
-64.5 M NET INCOME
-71.06%
Growth Rates
1Year -71.06%
3Years -26.73%
5Years 0.00%
7Years 0.00%
10Years 0.00%
-52.1 M OPERATING CASH FLOW
-13.54%
Growth Rates
1Year -13.54%
3Years -41.79%
5Years 0.00%
7Years 0.00%
10Years 0.00%
-267 K INVESTING CASH FLOW
53.65%
Growth Rates
1Year 53.65%
3Years -32.88%
5Years 0.00%
7Years 0.00%
10Years 0.00%
101 M FINANCING CASH FLOW
183483.64%
Growth Rates
1Year 183483.64%
3Years 107.59%
5Years 0.00%
7Years 0.00%
10Years 0.00%
0 REVENUE
0.00%
Growth Rates
1Year 0.00%
3Years 0.00%
5Years 0.00%
7Years 0.00%
10Years 0.00%
-19.9 M OPERATING INCOME
-24.36%
Growth Rates
1Year -34.50%
3Years -49.32%
5Years 0.00%
7Years 0.00%
10Years 0.00%
-48.9 M NET INCOME
-235.16%
Growth Rates
1Year -71.06%
3Years -26.73%
5Years 0.00%
7Years 0.00%
10Years 0.00%
-40.8 M OPERATING CASH FLOW
-249.22%
Growth Rates
1Year -13.54%
3Years -41.79%
5Years 0.00%
7Years 0.00%
10Years 0.00%
-674 K INVESTING CASH FLOW
-329.45%
Growth Rates
1Year 53.65%
3Years -32.88%
5Years 0.00%
7Years 0.00%
10Years 0.00%
47.5 M FINANCING CASH FLOW
26164.64%
Growth Rates
1Year 183483.64%
3Years 107.59%
5Years 0.00%
7Years 0.00%
10Years 0.00%
Balance Sheet Decomposition Jasper Therapeutics, Inc.
image
Current Assets 88.9 M
Cash & Short-Term Investments 86.9 M
Receivables 250 K
Other Current Assets 1.8 M
Non-Current Assets 5.95 M
Long-Term Investments 0
PP&E 4.19 M
Other Non-Current Assets 1.76 M
Current Liabilities 12.4 M
Accounts Payable 4.15 M
Short-Term Debt 1.94 M
Other Current Liabilities 6.28 M
Non-Current Liabilities 4.08 M
Long-Term Debt 1.81 M
Other Non-Current Liabilities 2.26 M
EFFICIENCY
Earnings Waterfall Jasper Therapeutics, Inc.
image
Revenue 0
Cost Of Revenue 1.11 M
Gross Profit -1.11 M
Operating Expenses 68.9 M
Operating Income -68.9 M
Other Expenses -4.4 M
Net Income -64.5 M
RATIOS
0.00% GROSS MARGIN
0.00%
Averages
1Year 0.00%
3Years 0.00%
5Years 0.00%
7Years 0.00%
10Years 0.00%
0.00% OPERATING MARGIN
0.00%
Averages
1Year 0.00%
3Years 0.00%
5Years 0.00%
7Years 0.00%
10Years 0.00%
0.00% NET MARGIN
0.00%
Averages
1Year 0.00%
3Years 0.00%
5Years 0.00%
7Years 0.00%
10Years 0.00%
-82.18% ROE
-82.18%
Averages
1Year -82.18%
3Years -61.28%
5Years -23.47%
7Years 0.00%
10Years 0.00%
-67.94% ROA
-67.94%
Averages
1Year -67.94%
3Years -47.84%
5Years -59.49%
7Years 0.00%
10Years 0.00%
-84.58% ROIC
-84.58%
Averages
1Year -84.58%
3Years -71.62%
5Years -35.68%
7Years 0.00%
10Years 0.00%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Jasper Therapeutics, Inc.
image
Net Income -64.5 M
Depreciation & Amortization 1.11 M
Capital Expenditures -267 K
Stock-Based Compensation 5.21 M
Change in Working Capital 5.1 M
Others 3.04 M
Free Cash Flow -52.3 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Jasper Therapeutics, Inc.
image
JSPRW has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Jasper Therapeutics, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
31.1 K USD 1
9-12 MONTHS
Date Value Insider Amount Avg Price
11 months ago
Nov 28, 2023
Bought 6.49 K USD
WIGGANS THOMAS G
Director
+ 10000
 0.6486 USD
11 months ago
Nov 21, 2023
Bought 6.38 K USD
WIGGANS THOMAS G
Director
+ 10000
 0.6383 USD
11 months ago
Nov 20, 2023
Bought 6.31 K USD
WIGGANS THOMAS G
Director
+ 10000
 0.6309 USD
1 year ago
Nov 17, 2023
Bought 5.97 K USD
WIGGANS THOMAS G
Director
+ 10000
 0.5966 USD
1 year ago
Nov 16, 2023
Bought 5.96 K USD
WIGGANS THOMAS G
Director
+ 10000
 0.5965 USD
1 year ago
Oct 13, 2023
Sell 6.78 K USD
Lis William
Director
- 7965
 0.8508 USD
1 year ago
Jun 13, 2023
Sell 14.9 K USD
Mahal Jeetinder Singh
See Remarks
- 9000
 1.6572 USD
1 year ago
Apr 14, 2023
Sell 10.4 K USD
French Anna Louise
Director
- 7000
 1.48 USD
1 year ago
Apr 13, 2023
Sell 13.5 K USD
EMSTER KURT VON
Director
- 9075
 1.4903 USD
1 year ago
Apr 13, 2023
Sell 12.2 K USD
Lis William
Director
- 8500
 1.44 USD
1 year ago
Jan 27, 2023
Bought 4 M USD
Qiming U.S. Healthcare Fund II, L.P.
10 percent owner
+ 2666666
 1.5 USD
1 year ago
Jan 27, 2023
Bought 4.7 M USD
Carlyle Group Inc.
10 percent owner
+ 3133333
 1.5 USD
1 year ago
Jan 25, 2023
Sell 142 K USD
ROCHE HOLDING LTD
Director
- 75000
 1.89 USD
3 years ago
Apr 21, 2021
Sell 11.5 K USD
GLAZER CAPITAL, LLC
10 percent owner
- 1164
 9.92 USD
3 years ago
Apr 23, 2021
Sell 1.51 M USD
GLAZER CAPITAL, LLC
10 percent owner
- 151719
 9.92 USD
3 years ago
Apr 19, 2021
Sell 20.5 K USD
GLAZER CAPITAL, LLC
10 percent owner
- 2060
 9.97 USD
3 years ago
Feb 18, 2021
Sell 104 K USD
GLAZER CAPITAL, LLC
10 percent owner
- 10000
 10.45 USD
3 years ago
Feb 19, 2021
Sell 22.2 K USD
GLAZER CAPITAL, LLC
10 percent owner
- 2112
 10.5 USD
3 years ago
Feb 22, 2021
Sell 7.33 K USD
GLAZER CAPITAL, LLC
10 percent owner
- 698
 10.5 USD
3 years ago
Feb 05, 2021
Sell 2.2 K USD
GLAZER CAPITAL, LLC
10 percent owner
- 212
 10.4 USD
3 years ago
Jan 14, 2021
Sell 1.05 K USD
GLAZER CAPITAL, LLC
10 percent owner
- 101
 10.4 USD
3 years ago
Jan 08, 2021
Sell 102 K USD
GLAZER CAPITAL, LLC
10 percent owner
- 10000
 10.25 USD
3 years ago
Dec 29, 2020
Sell 184 USD
GLAZER CAPITAL, LLC
10 percent owner
- 18
 10.25 USD
3 years ago
Dec 30, 2020
Sell 769 USD
GLAZER CAPITAL, LLC
10 percent owner
- 75
 10.25 USD
3 years ago
Dec 22, 2020
Sell 102 K USD
GLAZER CAPITAL, LLC
10 percent owner
- 10000
 10.15 USD
3 years ago
Dec 28, 2020
Sell 102 K USD
GLAZER CAPITAL, LLC
10 percent owner
- 10000
 10.2 USD
3 years ago
Dec 11, 2020
Sell 50.2 K USD
GLAZER CAPITAL, LLC
10 percent owner
- 5000
 10.05 USD
3 years ago
Dec 14, 2020
Sell 50.2 K USD
GLAZER CAPITAL, LLC
10 percent owner
- 5000
 10.05 USD
3 years ago
Dec 15, 2020
Sell 102 K USD
GLAZER CAPITAL, LLC
10 percent owner
- 10000
 10.15 USD
4 years ago
Sep 04, 2020
Sell 118 USD
GLAZER CAPITAL, LLC
10 percent owner
- 11
 10.73 USD
3 years ago
Dec 07, 2020
Sell 10.1 USD
GLAZER CAPITAL, LLC
10 percent owner
- 1
 10.05 USD
4 years ago
Sep 21, 2020
Sell 10 K USD
GLAZER CAPITAL, LLC
10 percent owner
- 1000
 10 USD
4 years ago
Sep 16, 2020
Sell 200 USD
GLAZER CAPITAL, LLC
10 percent owner
- 20
 9.99 USD
4 years ago
Sep 18, 2020
Sell 10 K USD
GLAZER CAPITAL, LLC
10 percent owner
- 1000
 10 USD
4 years ago
Sep 11, 2020
Sell 6.81 K USD
GLAZER CAPITAL, LLC
10 percent owner
- 682
 9.99 USD
4 years ago
Sep 15, 2020
Sell 7.99 K USD
GLAZER CAPITAL, LLC
10 percent owner
- 800
 9.99 USD
4 years ago
Sep 08, 2020
Sell 9.99 USD
GLAZER CAPITAL, LLC
10 percent owner
- 1
 9.99 USD
4 years ago
Aug 13, 2020
Sell 17 K USD
GLAZER CAPITAL, LLC
10 percent owner
- 1699
 9.99 USD
4 years ago
Aug 17, 2020
Sell 17 K USD
GLAZER CAPITAL, LLC
10 percent owner
- 1699
 9.99 USD
7. News
8. Profile Summary

Jasper Therapeutics, Inc. JSPRW

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 332 M
Dividend Yield 0.00%
Description Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and novel conditioning regimens for stem cell transplantation and ex-vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is headquartered in Redwood City, California.
Contact 2200 Bridge Pkwy, Redwood City, 94065 https://www.jaspertherapeutics.com/
IPO Date None
Employees 45
Officers Dr. Wendy Pang M.D., Ph.D. Senior Vice President of Research & Translational Medicine Mr. David Ku M.D. Vice President of Corporate Development, Portfolio Strategy & Management Mr. Jeetinder Singh Mahal M.B.A. Chief Operating Officer Dr. Luca Di Noto Ph.D. Senior Vice President of Technical Operations Dr. Judith Anne Shizuru M.D., Ph.D. Co-Founder & Director Dr. Edwin Jonathan Tucker M.D. Chief Medical Officer Mr. Matthew Ford Vice President of Human Resources Mr. Ronald A. Martell President, Chief Executive Officer & Director Ms. Patricia Carlos Senior Vice President of Regulatory Affairs & Quality